Saft C - Search Results

1

Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohort.

Achenbach J, Saft C, Faissner S, Ellrichmann G. Achenbach J, et al. Among authors: saft c. Ther Adv Neurol Disord. 2022 Jul 23;15:17562864221109750. doi: 10.1177/17562864221109750. eCollection 2022. Ther Adv Neurol Disord. 2022. PMID: 35899100 Free PMC article.

2

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, Gold R, Linker RA. Ellrichmann G, et al. Among authors: saft c. PLoS One. 2011 Jan 31;6(1):e16172. doi: 10.1371/journal.pone.0016172. PLoS One. 2011. PMID: 21297955 Free PMC article.

3

Teaching Video NeuroImages: spinal and bulbar muscular atrophy mimicking essential tremor.

Kerasnoudis A, Ellrichmann G, Gold R, Saft C. Kerasnoudis A, et al. Among authors: saft c. Neurology. 2012 Feb 7;78(6):e41. doi: 10.1212/WNL.0b013e318245d2bd. Neurology. 2012. PMID: 22311934 No abstract available.

4

The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.

Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network; Nguyen HP. Metzger S, et al. PLoS One. 2013 Jul 22;8(7):e68951. doi: 10.1371/journal.pone.0068951. Print 2013. PLoS One. 2013. PMID: 23894380 Free PMC article.

5

The role of the immune system in Huntington's disease.

Ellrichmann G, Reick C, Saft C, Linker RA. Ellrichmann G, et al. Among authors: saft c. Clin Dev Immunol. 2013;2013:541259. doi: 10.1155/2013/541259. Epub 2013 Jul 15. Clin Dev Immunol. 2013. PMID: 23956761 Free PMC article. Review.

6

Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.

Reick C, Ellrichmann G, Thöne J, Scannevin RH, Saft C, Linker RA, Gold R. Reick C, et al. Among authors: saft c. Exp Neurol. 2014 Jul;257:50-6. doi: 10.1016/j.expneurol.2014.04.003. Epub 2014 Apr 13. Exp Neurol. 2014. PMID: 24731948

7

β-Defensin genomic copy number does not influence the age of onset in Huntington's Disease.

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; Registry investigators of the European Huntington's Disease Network. Vittori A, et al. J Huntingtons Dis. 2013;2(1):107-24. doi: 10.3233/JHD-130002. J Huntingtons Dis. 2013. PMID: 25057107

8

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.

Lee DH, Heidecke H, Schröder A, Paul F, Wachter R, Hoffmann R, Ellrichmann G, Dragun D, Waschbisch A, Stegbauer J, Klotz P, Gold R, Dechend R, Müller DN, Saft C, Linker RA. Lee DH, et al. Among authors: saft c. Mol Neurodegener. 2014 Nov 15;9:49. doi: 10.1186/1750-1326-9-49. Mol Neurodegener. 2014. PMID: 25398321 Free PMC article.

9

Echogenicity of basal ganglia structures in different Huntington's disease phenotypes.

Saft C, Hoffmann R, Strassburger-Krogias K, Lücke T, Meves SH, Ellrichmann G, Krogias C. Saft C, et al. J Neural Transm (Vienna). 2015 Jun;122(6):825-33. doi: 10.1007/s00702-014-1335-7. Epub 2014 Dec 13. J Neural Transm (Vienna). 2015. PMID: 25503829

10

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network. Cubo E, et al. Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8. Neurology. 2016. PMID: 27402890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page